Harold Brakewood

Corporate Officer/Principal at IMMUNEERING CORPORATION

Net worth: 63 758 $ as of 2026-05-30

61 year

Consumer Services

Health Technology

Profile

Harold E.
Brakewood is Chief Business Officer at Immuneering Corp.
since 2023.
From 2015 to 2021, served as Vice President & Head-Oncology Business Unit at Regeneron Pharmaceuticals, Inc. Education includes undergraduate degree from Bowdoin College, graduate degree from Dartmouth College, and MBA from Harvard Business School.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
IMMUNEERING CORP. CLASS A 0.02%	2026-02-02	11,050 ( 0.02% )	63 759 $	2026-05-30

Harold Brakewood active positions

Companies	Position	Start
IMMUNEERING CORPORATION	Corporate Officer/Principal	2023-03-27

All active positions of Harold Brakewood

Former positions of Harold Brakewood

Companies	Position	End
REGENERON PHARMACEUTICALS, INC.	Corporate Officer/Principal	2021-11-30

See the detail of Harold Brakewood's experience

Training of Harold Brakewood

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Harold Brakewood's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases	Health Technology
Dartmouth College Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Bowdoin College Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Harvard Business School Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Immuneering Corp. Immuneering Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, focuses on the oncology and neuroscience product candidates	Health Technology